Evidence map›Paper›PMID 41403448›Full record

ArticleFrontiers in pharmacology2025

Machine learning-based prognostic modeling for locally advanced non-small cell lung cancer treated with immuno-radiotherapy.

Simin Lu, Xin Zheng, Yi Wang, Yafei Li, Xuan Yu, Yan Zhang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Simin LuDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Xin ZhengDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Yi WangDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Yafei LiDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Xuan YuDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yan ZhangDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with locally advanced non-small cell lung cancer (NSCLC) who undergo concurrent chemoradiotherapy (CCRT) followed by consolidation immunotherapy show heterogeneous survival outcomes. Accurate prognostic prediction remains a major challenge in clinical practice. This study aimed to develop machine learning models to enhance personalized outcome prediction and guide precision immuno-radiotherapy. Methods: A total of 219 patients with locally advanced NSCLC were retrospectively enrolled. All patients received standard CCRT followed by consolidation immunotherapy. Prognostic variables were first selected using least absolute shrinkage and selection operator (LASSO) regression. A multivariate Cox proportional hazards model and a random survival forest (RSF) model were then constructed in the training cohort and validated in the independent cohort. Results: LASSO regression identified four prognostic variables: Age, T stage, Stage, and Pathology. Multivariate Cox analysis confirmed Stage and Pathology as independent predictors of OS. The Cox model achieved a C-index of 0.62 and Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of 0.748 and 0.736 for 1-and 2-year OS in the validation cohort. The RSF model demonstrated higher predictive accuracy, with a C-index of 0.67 and AUC-ROC of 0.79 and 0.78 for 1-and 2-year OS, respectively. Variable importance analysis indicated that Stage and Pathology were the most influential factors. Based on RSF-derived risk scores, patients were stratified into high-and low-risk groups, and the high-risk group showed significantly poorer survival. Conclusion: The RSF model demonstrated improved performance compared to the conventional Cox model in predicting survival and stratifying risk among patients with locally advanced NSCLC undergoing CCRT and consolidation immunotherapy.

Indexed as

artificial intelligencechemoradiotherapyimmunotherapynon-small cell lung cancerrandom survival forest

Identifiers

PMID41403448
PMCPMC12702944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.